Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
06 Dec 2023
Historique:
medline: 11 12 2023
pubmed: 6 12 2023
entrez: 6 12 2023
Statut: ppublish

Résumé

Late diagnosis and the lack of screening methods for early detection define high-grade serous ovarian cancer (HGSOC) as the gynecological malignancy with the highest mortality rate. In the work presented here, we investigated a retrospective and multicentric cohort of 250 archival Papanicolaou (Pap) test smears collected during routine gynecological screening. Samples were taken at different time points (from 1 month to 13.5 years before diagnosis) from 113 presymptomatic women who were subsequently diagnosed with HGSOC (pre-HGSOC) and from 77 healthy women. Genome instability was detected through low-pass whole-genome sequencing of DNA derived from Pap test samples in terms of copy number profile abnormality (CPA). CPA values of DNA extracted from Pap test samples from pre-HGSOC women were substantially higher than those in samples from healthy women. Consistently with the longitudinal analysis of clonal pathogenic

Identifiants

pubmed: 38055801
doi: 10.1126/scitranslmed.adi2556
doi:

Substances chimiques

DNA 9007-49-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadi2556

Auteurs

Lara Paracchini (L)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan 20072, Italy.
Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan 20089, Italy.

Laura Mannarino (L)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan 20072, Italy.
Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan 20089, Italy.

Chiara Romualdi (C)

Department of Biology, University of Padua, Padua 35121, Italy.

Riccardo Zadro (R)

Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan 20089, Italy.

Luca Beltrame (L)

Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan 20089, Italy.

Ilaria Fuso Nerini (I)

Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan 20089, Italy.

Paolo Zola (P)

Department of Surgical Science, University of Turin, Turin 10126, Italy.

Maria E Laudani (ME)

Department of Surgical Science, University of Turin, Turin 10126, Italy.

Eva Pagano (E)

Unit of Clinical Epidemiology, Città della Salute e della Scienza Hospital, University of Turin and CPO Piemonte, Turin 10126, Italy.

Livia Giordano (L)

Unit of Clinical Epidemiology, Città della Salute e della Scienza Hospital, University of Turin and CPO Piemonte, Turin 10126, Italy.

Robert Fruscio (R)

Department of Obstetrics and Gynaecology, Università degli Studi Milano-Bicocca, Fondazione IRCCS San Gerardo dei Tintori, Monza 20900, Italy.

Fabio Landoni (F)

Department of Obstetrics and Gynaecology, Università degli Studi Milano-Bicocca, Fondazione IRCCS San Gerardo dei Tintori, Monza 20900, Italy.

Silvia Franceschi (S)

Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Pordenone 33081, Italy.
Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Milan 20132, Italy.

Maria L Dalessandro (ML)

Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan 20089, Italy.

Vincenzo Canzonieri (V)

Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Pordenone 33081, Italy.
Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste 34149, Italy.

Luca Bocciolone (L)

Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Milan 20132, Italy.

Domenica Lorusso (D)

Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.

Cristina Bosetti (C)

Unit of Cancer Epidemiology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan 20156, Italy.

Francesco Raspagliesi (F)

Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan 20133, Italy.

Isabella M G Garassino (IMG)

Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Rozzano, Milan 20089, Italy.

Maurizio D'Incalci (M)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan 20072, Italy.
Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan 20089, Italy.

Sergio Marchini (S)

Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan 20089, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH